Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral mc4r Agonist LB54640 in Hypothalamic Obesity 6.2 Other Significant Developments 6.2.1 Feb 20, 2024: Mestag ...

Kisspeptin-10 (KP-10) peptide, a derivative of the larger kisspeptin protein family, has garnered interest in recent years due to its molecular structure and potential to influence various ...

Low testosterone or testosterone deficiency, also known as hypogonadism, is a condition in which patients develop symptoms.

CSTI-500 is under clinical development by ConSynance Therapeutics and currently in Phase I for Prader-Willi Syndrome (PWS).

Rhythm Pharmaceuticals (RYTM – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram ...

The US Food and Drug Administration (FDA) on Friday approved an expanded indication for Imcivree (setmelanotide), from Boston ...

Researchers at CRCHUM found that targeting the enzyme ABHD6 in specific brain regions of mice reduces obesity without causing ...

Learn the science behind yoga for stress relief, plus a 10-minute flow that can help calm you down during the busiest of ...

Mentions of trauma impacts, child abuse, sexual assault, self harm, alcohol and drug abuseSocial media and pop psychology have popularised the ...

Meditation and yoga are powerful tools for healing. They reduce stress and inflammation. These practices improve cognitive ...

A previously unknown population of neurons in the hypothalamus may pave the way for new obesity treatments. Obesity impacts a ...

In the third quarter of 2024, revenue of $23.3 million, or 70% of product revenue, was generated in the U.S. Oppenheimer is ...